Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Menée sur des lignées cellulaires de myélome multiple, cette étude montre qu'un ensemble de super-amplificateurs associés à des oncogènes, notamment MYC, sont occupés par le coactivateur transcriptionnel BRD4 et que l'inhibition de BRD4 est susceptible d'induire la répression sélective de ces gènes
Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types. º BRD4 and Mediator occupy super-enhancers in tumor cells º Super-enhancers are preferentially affected by BET bromodomain inhibition º Super-enhancers drive expression of oncogenes in multiple cancers A small set of super-enhancers associated with oncogenes such as MYC was co-occupied by BRD4 and mediator in multiple myeloma. Inhibition of BRD4 leads to selective repression of these genes.